Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (MIRA), an emerging growth company incorporated in Florida, filed this Form 8-K on August 7, 2024. The report addresses a specific corporate governance event regarding its listing status on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report focused solely on regulatory compliance status.
Material Changes
The primary material event reported is the Company's receipt of notification from Nasdaq on August 7, 2024, confirming that MIRA has regained compliance with Nasdaq Listing Rule 5550(a)(2) concerning the minimum bid price requirement. Consequently, the Company has resolved all previously cited issues and is in good standing with all applicable requirements for continued listing.
Guidance, Outlook, and Risks
Management expressed satisfaction with regaining compliance and stated an intention to continue adhering to Nasdaq listing standards. The filing does not provide forward-looking financial guidance, discuss specific operational risks, or detail contingencies beyond the resolution of the listing deficiency.
Investor Verification Checklist
- Verify the current trading price of MIRA stock to ensure it remains above the Nasdaq minimum bid price requirement.
- Confirm the Company's continued good standing status on The Nasdaq Capital Market via the exchange's official website.
- Review prior 8-K filings to understand the timeline and nature of the previous non-compliance period.